| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| WSD-0922 | WSD0922; WSD-0922 | Phase 2 Clinical | Wayshine Biopharm International Ltd | Glioblastoma; Neoplasms; Astrocytoma; Carcinoma, Non-Small-Cell Lung | 상세 |
| Anti-EGFRvIII-CAR | EGFRvIII CAR; Anti-EGFRvIII-CAR | Phase 2 Clinical | National Cancer Institute | Glioblastoma; Brain Neoplasms; Gliosarcoma; Glioma | 상세 |
| Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) | CPGJ-602; 602; CPGJ602; CPGJ 602 | Phase 2 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Colorectal Neoplasms | 상세 |
| EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) | LXF-821 | Phase 1 Clinical | University Of Pennsylvania, Novartis Pharma Ag | Glioblastoma | 상세 |
| EGFRvIII-CAR | Phase 1 Clinical | Duke University Medical Center | Glioblastoma | 상세 | |
| APTN-101 | APTN 101 | Phase 1 Clinical | Glioblastoma | 상세 | |
| Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine) | Phase 1 Clinical | California Institute For Regenerative Medicine, National Cancer Institute | Glioblastoma | 상세 | |
| Targeted EGFRvIII autochimeric antigen receptor T cell therapy (DCTY) | DCTY0801; DCTY-0801 | Phase 1 Clinical | Beijing DCTY Biotech Co Ltd | Glioblastoma | 상세 |
| SNC-109 | SNC109; SNC-109 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Glioblastoma | 상세 |
| RO-7428731 | RO-7428731; RG-6156 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Glioblastoma | 상세 |
| hEGFRvIII-CD3 Bi-scFv | Phase 1 Clinical | Duke University | Glioblastoma; Glioma | 상세 | |
| GNC-039 | GNC-039 | Phase 1 Clinical | Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis | 상세 | |
| Etevritamab | AMG-596 | Phase 1 Clinical | Amgen Inc | Glioblastoma | 상세 |

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호



